Ritam Bandopadhyay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ritam Bandopadhyay has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Awanish Mishra
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) - Guwahati, Changsari, Kamrup, Assam 781101, India
6 shared publications - Javed Ahmad
Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia
3 shared publications Pragya Shakti Mishra
3 shared publicationsAwanish Mishra
2 shared publications- Christina Piperi
Department of Biological Chemistry, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
2 shared publications - Efthalia Angelopoulou
1st Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
2 shared publications
Latest Publications
- 20 February 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 38 (3) , 873-919
Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research
Parkinson’s disease (PD) is one of the progressive neurological diseases which affect around 10 million population worldwide. The clinical manifestation of motor symptoms in PD patients appears later when most dopaminergic neurons have degenerated. Thus, for better management of PD, the development of accurate biomarkers for the early prognosis of PD is imperative. The present work will discuss the potential biomarkers from various attributes covering biochemical, microRNA, and neuroimaging aspects (α-synuclein, DJ-1, UCH-L1, β-glucocerebrosidase, BDNF, etc.) for diagnosis, recent development in PD management, and major limitations with current and conventional anti-Parkinson therapy. This manuscript summarizes potential biomarkers and therapeutic targets, based on available preclinical and clinical evidence, for better management of PD.
- 20 February 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 38 (3) , 873-919
Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research
Parkinson’s disease (PD) is one of the progressive neurological diseases which affect around 10 million population worldwide. The clinical manifestation of motor symptoms in PD patients appears later when most dopaminergic neurons have degenerated. Thus, for better management of PD, the development of accurate biomarkers for the early prognosis of PD is imperative. The present work will discuss the potential biomarkers from various attributes covering biochemical, microRNA, and neuroimaging aspects (α-synuclein, DJ-1, UCH-L1, β-glucocerebrosidase, BDNF, etc.) for diagnosis, recent development in PD management, and major limitations with current and conventional anti-Parkinson therapy. This manuscript summarizes potential biomarkers and therapeutic targets, based on available preclinical and clinical evidence, for better management of PD.
- Open Access
- 1 November 2022
- Published by MDPI AG in Bioengineering
- Vol. 9 (11) , 631
Utilization of Nanotechnology to Improve Bone Health in Osteoporosis Exploiting Nigella sativa and Its Active Constituent Thymoquinone
Osteoporosis, a chronic bone disorder, is one of the leading causes of fracture and morbidity risk. Numerous medicinally important herbs have been evaluated for their efficacy in improving bone mass density in exhaustive preclinical and limited clinical studies. Nigella sativa L. has been used as local folk medicine, and traditional healers have used it to manage various ailments. Its reported beneficial effects include controlling bone and joint diseases. The present manuscript aimed to provide a sound discussion on the pharmacological evidence of N. sativa and its active constituent, thymoquinone, for its utility in the effective management of osteoporosis. N. sativa is reported to possess anti-IL-1 and anti-TNF-α-mediated anti-inflammatory effects, leading to positive effects on bone turnover markers, such as alkaline phosphatase and tartrate-resistant acid phosphatase. It is reported to stimulate bone regeneration by prompting osteoblast proliferation, ossification, and decreasing osteoclast cells. Thymoquinone from N. sativa has exhibited an antioxidant effect on bone tissue by reducing the FeNTA-induced oxidative stress. The present manuscript highlights phytochemistry, pharmacological effect, and the important mechanistic perspective of N. sativa and its active constituents for the management of osteoporosis. Further, it also provides sound discussion on the utilization of a nanotechnology-mediated drug delivery approach as a promising strategy to improve the therapeutic performance of N. sativa and its active constituent, thymoquinone, in the effective management of osteoporosis.
- 1 November 2022
- Published by MDPI AG in Bioengineering
- Vol. 9 (11) , 631
Open AccessUtilization of Nanotechnology to Improve Bone Health in Osteoporosis Exploiting Nigella sativa and Its Active Constituent Thymoquinone
Osteoporosis, a chronic bone disorder, is one of the leading causes of fracture and morbidity risk. Numerous medicinally important herbs have been evaluated for their efficacy in improving bone mass density in exhaustive preclinical and limited clinical studies. Nigella sativa L. has been used as local folk medicine, and traditional healers have used it to manage various ailments. Its reported beneficial effects include controlling bone and joint diseases. The present manuscript aimed to provide a sound discussion on the pharmacological evidence of N. sativa and its active constituent, thymoquinone, for its utility in the effective management of osteoporosis. N. sativa is reported to possess anti-IL-1 and anti-TNF-α-mediated anti-inflammatory effects, leading to positive effects on bone turnover markers, such as alkaline phosphatase and tartrate-resistant acid phosphatase. It is reported to stimulate bone regeneration by prompting osteoblast proliferation, ossification, and decreasing osteoclast cells. Thymoquinone from N. sativa has exhibited an antioxidant effect on bone tissue by reducing the FeNTA-induced oxidative stress. The present manuscript highlights phytochemistry, pharmacological effect, and the important mechanistic perspective of N. sativa and its active constituents for the management of osteoporosis. Further, it also provides sound discussion on the utilization of a nanotechnology-mediated drug delivery approach as a promising strategy to improve the therapeutic performance of N. sativa and its active constituent, thymoquinone, in the effective management of osteoporosis.
- Open Access
- 7 April 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 805388
Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
Parkinson’s disease (PD) is the second leading neurodegenerative disease that is characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been considered a mainstay for the management of PD; however, its prolonged treatment is often associated with abnormal involuntary movements and results in L-DOPA-induced dyskinesia (LID). Although LID is encountered after chronic administration of L-DOPA, the appearance of dyskinesia after weeks or months of the L-DOPA treatment has complicated our understanding of its pathogenesis. Pathophysiology of LID is mainly associated with alteration of direct and indirect pathways of the cortico-basal ganglia-thalamic loop, which regulates normal fine motor movements. Hypersensitivity of dopamine receptors has been involved in the development of LID; moreover, these symptoms are worsened by concurrent non-dopaminergic innervations including glutamatergic, serotonergic, and peptidergic neurotransmission. The present study is focused on discussing the recent updates in molecular mechanisms and therapeutic approaches for the effective management of LID in PD patients.
- 7 April 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 805388
Open AccessMolecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
Parkinson’s disease (PD) is the second leading neurodegenerative disease that is characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been considered a mainstay for the management of PD; however, its prolonged treatment is often associated with abnormal involuntary movements and results in L-DOPA-induced dyskinesia (LID). Although LID is encountered after chronic administration of L-DOPA, the appearance of dyskinesia after weeks or months of the L-DOPA treatment has complicated our understanding of its pathogenesis. Pathophysiology of LID is mainly associated with alteration of direct and indirect pathways of the cortico-basal ganglia-thalamic loop, which regulates normal fine motor movements. Hypersensitivity of dopamine receptors has been involved in the development of LID; moreover, these symptoms are worsened by concurrent non-dopaminergic innervations including glutamatergic, serotonergic, and peptidergic neurotransmission. The present study is focused on discussing the recent updates in molecular mechanisms and therapeutic approaches for the effective management of LID in PD patients.
- 21 January 2022
- Published by Taylor & Francis
- p. 427-440
Opioid Activity
Bioactive peptides are thought to play a crucial role in maintaining the human health by exhibiting their action on different systems of the human body such as endocrine, cardiovascular, or digestive actions, including actions on the immune and nervous systems. They can be obtained from amino acids and are covalently bonded together by amide and peptide bonds. Since these peptides are derived from natural sources, such as plants and animal products, they have an advantage over synthetic drugs as they produce the least side effects. They can be used to prevent degradation of foods by microbes, diseases, such as cancer, depression, and many more. In this study, we have tried to find the various sources through which these peptides can be obtained, their analysis, and functions.
- 21 January 2022
- Published by Taylor & Francis
- p. 427-440
Opioid Activity
Bioactive peptides are thought to play a crucial role in maintaining the human health by exhibiting their action on different systems of the human body such as endocrine, cardiovascular, or digestive actions, including actions on the immune and nervous systems. They can be obtained from amino acids and are covalently bonded together by amide and peptide bonds. Since these peptides are derived from natural sources, such as plants and animal products, they have an advantage over synthetic drugs as they produce the least side effects. They can be used to prevent degradation of foods by microbes, diseases, such as cancer, depression, and many more. In this study, we have tried to find the various sources through which these peptides can be obtained, their analysis, and functions.
- 21 January 2022
- Published by Taylor & Francis
- p. 365-390
Antihypertensive Activity
Hypertension is one of the most common non-communicable disorders which is clinically represented by elevated systolic and diastolic blood pressure. Food-derived bioactive peptides have demonstrated the potential to alleviate elevated blood pressure. The renin-angiotensin-aldosterone system (RAAS) is widely recognized in the regulation of blood pressure and through this approach various antihypertensive approaches have been derived. The present work summarizes an overview of different sources of foodborne bioactive peptides, their extraction and isolation, and their potential antihypertensive mechanisms. This chapter will be a suitable literature supplement for researchers and will provide awareness of food-derived bioactive peptides as an alternative therapy for hypertension.
- 21 January 2022
- Published by Taylor & Francis
- p. 365-390
Antihypertensive Activity
Hypertension is one of the most common non-communicable disorders which is clinically represented by elevated systolic and diastolic blood pressure. Food-derived bioactive peptides have demonstrated the potential to alleviate elevated blood pressure. The renin-angiotensin-aldosterone system (RAAS) is widely recognized in the regulation of blood pressure and through this approach various antihypertensive approaches have been derived. The present work summarizes an overview of different sources of foodborne bioactive peptides, their extraction and isolation, and their potential antihypertensive mechanisms. This chapter will be a suitable literature supplement for researchers and will provide awareness of food-derived bioactive peptides as an alternative therapy for hypertension.
- Open Access
Neuroprotective Potential of Chrysin: Mechanistic Insights and Therapeutic Potential for Neurological Disorders
Chrysin, a herbal bioactive molecule, exerts a plethora of pharmacological effects, including anti-oxidant, anti-inflammatory, neuroprotective, and anti-cancer. A growing body of evidence has highlighted the emerging role of chrysin in a variety of neurological disorders, including Alzheimer’s and Parkinson’s disease, epilepsy, multiple sclerosis, ischemic stroke, traumatic brain injury, and brain tumors. Based on the results of recent pre-clinical studies and evidence from studies in humans, this review is focused on the molecular mechanisms underlying the neuroprotective effects of chrysin in different neurological diseases. In addition, the potential challenges, and opportunities of chrysin’s inclusion in the neurotherapeutics repertoire are critically discussed.
Open AccessNeuroprotective Potential of Chrysin: Mechanistic Insights and Therapeutic Potential for Neurological Disorders
Chrysin, a herbal bioactive molecule, exerts a plethora of pharmacological effects, including anti-oxidant, anti-inflammatory, neuroprotective, and anti-cancer. A growing body of evidence has highlighted the emerging role of chrysin in a variety of neurological disorders, including Alzheimer’s and Parkinson’s disease, epilepsy, multiple sclerosis, ischemic stroke, traumatic brain injury, and brain tumors. Based on the results of recent pre-clinical studies and evidence from studies in humans, this review is focused on the molecular mechanisms underlying the neuroprotective effects of chrysin in different neurological diseases. In addition, the potential challenges, and opportunities of chrysin’s inclusion in the neurotherapeutics repertoire are critically discussed.
- Open Access
Recent Developments in Diagnosis of Epilepsy: Scope of MicroRNA and Technological Advancements
Epilepsy is one of the most common neurological disorders, characterized by recurrent seizures, resulting from abnormally synchronized episodic neuronal discharges. Around 70 million people worldwide are suffering from epilepsy. The available antiepileptic medications are capable of controlling seizures in around 60–70% of patients, while the rest remain refractory. Poor seizure control is often associated with neuro-psychiatric comorbidities, mainly including memory impairment, depression, psychosis, neurodegeneration, motor impairment, neuroendocrine dysfunction, etc., resulting in poor prognosis. Effective treatment relies on early and correct detection of epileptic foci. Although there are currently a few well-established diagnostic techniques for epilepsy, they lack accuracy and cannot be applied to patients who are unsupportive or harbor metallic implants. Since a single test result from one of these techniques does not provide complete information about the epileptic foci, it is necessary to develop novel diagnostic tools. Herein, we provide a comprehensive overview of the current diagnostic tools of epilepsy, including electroencephalography (EEG) as well as structural and functional neuroimaging. We further discuss recent trends and advances in the diagnosis of epilepsy that will enable more effective diagnosis and clinical management of patients.
Open AccessRecent Developments in Diagnosis of Epilepsy: Scope of MicroRNA and Technological Advancements
Epilepsy is one of the most common neurological disorders, characterized by recurrent seizures, resulting from abnormally synchronized episodic neuronal discharges. Around 70 million people worldwide are suffering from epilepsy. The available antiepileptic medications are capable of controlling seizures in around 60–70% of patients, while the rest remain refractory. Poor seizure control is often associated with neuro-psychiatric comorbidities, mainly including memory impairment, depression, psychosis, neurodegeneration, motor impairment, neuroendocrine dysfunction, etc., resulting in poor prognosis. Effective treatment relies on early and correct detection of epileptic foci. Although there are currently a few well-established diagnostic techniques for epilepsy, they lack accuracy and cannot be applied to patients who are unsupportive or harbor metallic implants. Since a single test result from one of these techniques does not provide complete information about the epileptic foci, it is necessary to develop novel diagnostic tools. Herein, we provide a comprehensive overview of the current diagnostic tools of epilepsy, including electroencephalography (EEG) as well as structural and functional neuroimaging. We further discuss recent trends and advances in the diagnosis of epilepsy that will enable more effective diagnosis and clinical management of patients.
- 13 August 2021
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 36 (7) , 1591-1626
Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside
Neuroinflammation is one of the host defensive mechanisms through which the nervous system protects itself from pathogenic and or infectious insults. Moreover, neuroinflammation occurs as one of the most common pathological outcomes in various neurological disorders, makes it the promising target. The present review focuses on elaborating the recent advancement in understanding molecular mechanisms of neuroinflammation and its role in the etiopathogenesis of various neurological disorders, especially Alzheimer’s disease (AD), Parkinson’s disease (PD), and Epilepsy. Furthermore, the current status of anti-inflammatory agents in neurological diseases has been summarized in light of different preclinical and clinical studies. Finally, possible limitations and future directions for the effective use of anti-inflammatory agents in neurological disorders have been discussed.
- 13 August 2021
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 36 (7) , 1591-1626
Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside
Neuroinflammation is one of the host defensive mechanisms through which the nervous system protects itself from pathogenic and or infectious insults. Moreover, neuroinflammation occurs as one of the most common pathological outcomes in various neurological disorders, makes it the promising target. The present review focuses on elaborating the recent advancement in understanding molecular mechanisms of neuroinflammation and its role in the etiopathogenesis of various neurological disorders, especially Alzheimer’s disease (AD), Parkinson’s disease (PD), and Epilepsy. Furthermore, the current status of anti-inflammatory agents in neurological diseases has been summarized in light of different preclinical and clinical studies. Finally, possible limitations and future directions for the effective use of anti-inflammatory agents in neurological disorders have been discussed.
- 15 June 2021
- Published by Technoscience Academy in International Journal of Scientific Research in Science and Technology
- p. 885-893
A Unique Approach to Treat Rheumatic Heart Disease by Using In Silico Modeling With Polymeric Nanoparticles
Rheumatic heart disease (RHD) and its antecedent rheumatic fever (RF) is a serious health issue which targets mainly the elderly residing in developing countries. The main causative organism of RHD id group-A, β- hemolytic streptococci (GAS). It is basically an autoimmune disease triggered by GAS infection which damage the heart valve tissue, resulting in chest discomfort and pain. Both Diltiazem, a benzothiazepine class of voltage gated L-type Ca2+ channel blocker and Norfloxacin, a fluroquinolone class of drug, are active against hemolytic streptococci (GAS) class of pathogen. These drugs show no kind of drug interaction when used together. So, combination of both these to drugs can be used in the treatment of RHD. A polymeric nanoparticle formulation is very useful in formulating a combination of drugs, as, nano formulation increases the bioavailability of the drugs in systemic circulation, and they did not hinder each other’s absorption in the GIT. In this article we have developed and evaluated the polymeric nanoparticle formulation of norfloxacin and diltiazem combination, using chitosan as a polymer.
- 15 June 2021
- Published by Technoscience Academy in International Journal of Scientific Research in Science and Technology
- p. 885-893
A Unique Approach to Treat Rheumatic Heart Disease by Using In Silico Modeling With Polymeric Nanoparticles
Rheumatic heart disease (RHD) and its antecedent rheumatic fever (RF) is a serious health issue which targets mainly the elderly residing in developing countries. The main causative organism of RHD id group-A, β- hemolytic streptococci (GAS). It is basically an autoimmune disease triggered by GAS infection which damage the heart valve tissue, resulting in chest discomfort and pain. Both Diltiazem, a benzothiazepine class of voltage gated L-type Ca2+ channel blocker and Norfloxacin, a fluroquinolone class of drug, are active against hemolytic streptococci (GAS) class of pathogen. These drugs show no kind of drug interaction when used together. So, combination of both these to drugs can be used in the treatment of RHD. A polymeric nanoparticle formulation is very useful in formulating a combination of drugs, as, nano formulation increases the bioavailability of the drugs in systemic circulation, and they did not hinder each other’s absorption in the GIT. In this article we have developed and evaluated the polymeric nanoparticle formulation of norfloxacin and diltiazem combination, using chitosan as a polymer.